The Impact of Anthelmintic Treatment on the Incidence of Diarrheal Disease in Vietnamese School Children
Primary Purpose
Intestinal Helminthiasis, Diarrhea
Status
Withdrawn
Phase
Phase 4
Locations
Vietnam
Study Type
Interventional
Intervention
Albendazole
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Intestinal Helminthiasis focused on measuring Albendazole, Ancylostoma duodenale, Ascariasis lumbricoides, Coinfection, Diarrhea, Helminths, Necator americanus, Microbiota, Trichuris trichiura
Eligibility Criteria
Inclusion Criteria:
- Between 6-15 years of age
- Written informed consent from a parent or guardian
- Written assent from children >10 years of age
Exclusion Criteria:
- Subjects who do not fulfill any component of the inclusion criteria
- Subjects that are both hookworm-positive and anemic, as defined by the WHO guidelines
Sites / Locations
- Cu Chi, Viet Nam
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
Albendazole
Placebo
Arm Description
Albendazole will be administered as a single 400mg chewable tablet at 0, 3, 6, 9, and 12 months.
Matching Placebo will be administered as a single chewable tablet at 0, 3, 6, and 9 months. At month 12, all participants will receive a single 400mg Albendazole tablet.
Outcomes
Primary Outcome Measures
Incidence of diarrheal disease assessed by 12 months of weekly active and passive case surveillance
Incidence of diarrhea will be defined according to WHO guidelines as three or more loose stools in a 24-hour period or at least one bloody/mucoid stool. To be considered a new episode of diarrhea, at least three intervening days of normal stools without other gastrointestinal symptoms need to have passed between diarrhea occurrences.
Secondary Outcome Measures
Prevalence and intensity of soil-transmitted helminth infections by real-time PCR and microscopy
Prevalence and intensity of enteric viruses and bacteria that cause diarrhea assessed by real-time PCR and the Luminex xTAG Gastrointestinal Pathogen Panel
Changes in fecal microbiota composition by Illumina sequencing
Changes in blood cytokine (Th1, Th2, TH17, and Treg) levels by bead-based immunoassays
Antibody isotype response to helminth and diarrheal antigens by ELISA
Mean z-scores (height-for-age, weight-for-age, weight-for-height)
Full Information
NCT ID
NCT02597556
First Posted
November 3, 2015
Last Updated
December 14, 2016
Sponsor
Oxford University Clinical Research Unit, Vietnam
Collaborators
Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam, Ho Chi Minh Preventive Medicine Centre, Vietnam, Princeton University, Cu Chi Health Department
1. Study Identification
Unique Protocol Identification Number
NCT02597556
Brief Title
The Impact of Anthelmintic Treatment on the Incidence of Diarrheal Disease in Vietnamese School Children
Official Title
A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Impact of Anthelmintic Treatment on the Incidence of Diarrheal Disease in School Children in Southern Vietnam
Study Type
Interventional
2. Study Status
Record Verification Date
December 2016
Overall Recruitment Status
Withdrawn
Why Stopped
The prevalence of worm infections in the site is significantly lower than expected
Study Start Date
February 2016 (undefined)
Primary Completion Date
May 2016 (Actual)
Study Completion Date
May 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Oxford University Clinical Research Unit, Vietnam
Collaborators
Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam, Ho Chi Minh Preventive Medicine Centre, Vietnam, Princeton University, Cu Chi Health Department
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Cheap and effective drugs called 'anthelmintics' are routinely administered to children in developing countries to eliminate infections by parasitic helminths. However, the effects of anthelmintic treatment on other pathogens (e.g., bacteria, viruses, protozoa) remain unknown. The aim of this study is to investigate the impact of anthelmintic treatment on the incidence of viral- and bacterial-induced diarrhea in school children in southern Vietnam. Diarrheal disease remains a substantial cause of morbidity and mortality in children in Vietnam, and these children are typically co-infected with intestinal helminths. As helminths and diarrheal pathogens infect the same intestinal niche, anthelmintic treatments may alter host immune responses and the composition of the gut microbiota in ways that affect infection and disease risks caused by diarrheal pathogens.
This study will recruit 350 helminth-infected and 350 helminth-uninfected children aged 6-15 years. Recruited children will be randomized to receive either anthelmintic or placebo treatment once every three months and will be monitored for incidences of diarrheal disease for 12 months. At the 12-month time point, all children will receive anthelmintic treatment. Blood and stool samples will be collected throughout the study and used for evaluation of anemia and host immune responses, and for classification of gut microbes and parasite detection, respectively. The interventional study proposed here will provide an important first test of whether anthelmintic treatments have any indirect effects on infections caused by diarrheal pathogens.
Detailed Description
This study is a randomized, double-blind, placebo-controlled trial to evaluate the effects of 400 mg albendazole treatment against placebo on the incidence of diarrheal disease caused by viral and bacterial pathogens in school children in southern Vietnam. Children will be enrolled from three primary schools in Cu Chi district in Ho Chi Minh City, Vietnam. Children will be screened for infections by the four most common soil-transmitted helminths, Ascaris lumbricoides, Trichuris trichiura, Necator americanus, and Ancylostoma duodenale. Infected and uninfected individuals will be recruited into the study and randomized to either receive albendazole treatment once every three months for 12 months, or to placebo once every three months for 9 months, after which albendazole treatment will be given at month 12, in accordance with the current deworming schedule in Cu Chi district. A questionnaire regarding the participant's demographics, his/her daily habits, and potential sources of infection will be administered at baseline. Weekly active and passive surveillance of diarrheal cases will be conducted throughout the study, and a health questionnaire will be administered during all cases of diarrhea and at the end of the study.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Intestinal Helminthiasis, Diarrhea
Keywords
Albendazole, Ancylostoma duodenale, Ascariasis lumbricoides, Coinfection, Diarrhea, Helminths, Necator americanus, Microbiota, Trichuris trichiura
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Albendazole
Arm Type
Active Comparator
Arm Description
Albendazole will be administered as a single 400mg chewable tablet at 0, 3, 6, 9, and 12 months.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Matching Placebo will be administered as a single chewable tablet at 0, 3, 6, and 9 months. At month 12, all participants will receive a single 400mg Albendazole tablet.
Intervention Type
Drug
Intervention Name(s)
Albendazole
Intervention Description
A single 400mg dose of Albendazole administered at 0, 3, 6, 9, and 12 months.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Matching placebo tablet administered at 0, 3, 6, and 9 months. At month 12, all participants will receive a single dose of 400mg Albendazole.
Primary Outcome Measure Information:
Title
Incidence of diarrheal disease assessed by 12 months of weekly active and passive case surveillance
Description
Incidence of diarrhea will be defined according to WHO guidelines as three or more loose stools in a 24-hour period or at least one bloody/mucoid stool. To be considered a new episode of diarrhea, at least three intervening days of normal stools without other gastrointestinal symptoms need to have passed between diarrhea occurrences.
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Prevalence and intensity of soil-transmitted helminth infections by real-time PCR and microscopy
Time Frame
Baseline, 0.5, 3, 6, 6.5, 9, and 12 months, and during and two weeks after diarrhea cases
Title
Prevalence and intensity of enteric viruses and bacteria that cause diarrhea assessed by real-time PCR and the Luminex xTAG Gastrointestinal Pathogen Panel
Time Frame
Time Frame: Baseline, 3, 6, 9, and 12 months, and during and two weeks after diarrhea cases
Title
Changes in fecal microbiota composition by Illumina sequencing
Time Frame
Baseline, 0.5, 3, 6, 6.5, 9, and 12 months, and during and two weeks after diarrhea cases
Title
Changes in blood cytokine (Th1, Th2, TH17, and Treg) levels by bead-based immunoassays
Time Frame
Baseline, 6, and 12 months of study
Title
Antibody isotype response to helminth and diarrheal antigens by ELISA
Time Frame
Baseline, 6, and 12 months
Title
Mean z-scores (height-for-age, weight-for-age, weight-for-height)
Time Frame
Baseline and 12 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
6 Years
Maximum Age & Unit of Time
15 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Between 6-15 years of age
Written informed consent from a parent or guardian
Written assent from children >10 years of age
Exclusion Criteria:
Subjects who do not fulfill any component of the inclusion criteria
Subjects that are both hookworm-positive and anemic, as defined by the WHO guidelines
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Stephen Baker, PhD
Organizational Affiliation
Oxford University Clinical Research Unit
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Nghia Ho Dang Trung, PhD, MD
Organizational Affiliation
Pham Ngoc Thach University of Medicine
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Andrea Graham, PhD
Organizational Affiliation
Princeton University, USA
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Jacqueline Leung, MA
Organizational Affiliation
Princeton University, USA
Official's Role
Study Director
Facility Information:
Facility Name
Cu Chi, Viet Nam
City
Ho Chi Minh city
ZIP/Postal Code
700000
Country
Vietnam
12. IPD Sharing Statement
Citations:
PubMed Identifier
23986108
Citation
Blackwell AD, Martin M, Kaplan H, Gurven M. Antagonism between two intestinal parasites in humans: the importance of co-infection for infection risk and recovery dynamics. Proc Biol Sci. 2013 Aug 28;280(1769):20131671. doi: 10.1098/rspb.2013.1671. Print 2013 Oct 22.
Results Reference
background
PubMed Identifier
25574023
Citation
Ezenwa VO, Jolles AE. Epidemiology. Opposite effects of anthelmintic treatment on microbial infection at individual versus population scales. Science. 2015 Jan 9;347(6218):175-7. doi: 10.1126/science.1261714.
Results Reference
background
PubMed Identifier
19154651
Citation
Ferrari N, Cattadori IM, Rizzoli A, Hudson PJ. Heligmosomoides polygyrus reduces infestation of Ixodes ricinus in free-living yellow-necked mice, Apodemus flavicollis. Parasitology. 2009 Mar;136(3):305-16. doi: 10.1017/S0031182008005404. Epub 2009 Jan 21.
Results Reference
background
PubMed Identifier
23677343
Citation
Knowles SC, Fenton A, Petchey OL, Jones TR, Barber R, Pedersen AB. Stability of within-host-parasite communities in a wild mammal system. Proc Biol Sci. 2013 May 15;280(1762):20130598. doi: 10.1098/rspb.2013.0598. Print 2013 Jul 7.
Results Reference
background
PubMed Identifier
23658004
Citation
Pedersen AB, Antonovics J. Anthelmintic treatment alters the parasite community in a wild mouse host. Biol Lett. 2013 May 8;9(4):20130205. doi: 10.1098/rsbl.2013.0205. Print 2013 Aug 23.
Results Reference
background
PubMed Identifier
16798090
Citation
Nacher M. Worms and malaria: resisting the temptation to generalize. Trends Parasitol. 2006 Aug;22(8):350-1; author reply 351-2. doi: 10.1016/j.pt.2006.06.003. Epub 2006 Jun 23. No abstract available.
Results Reference
background
PubMed Identifier
7853436
Citation
Rousham EK. An increase in Giardia duodenalis infection among children receiving periodic Anthelmintic treatment in Bangladesh. J Trop Pediatr. 1994 Dec;40(6):329-33. doi: 10.1093/tropej/40.6.329.
Results Reference
background
PubMed Identifier
26202783
Citation
Taylor-Robinson DC, Maayan N, Soares-Weiser K, Donegan S, Garner P. Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin, and school performance. Cochrane Database Syst Rev. 2015 Jul 23;2015(7):CD000371. doi: 10.1002/14651858.CD000371.pub6.
Results Reference
background
PubMed Identifier
27266697
Citation
Leung JM, Hong CT, Trung NH, Thi HN, Minh CN, Thi TV, Hong DT, Man DN, Knowles SC, Wolbers M, Hoang Nle T, Thwaites G, Graham AL, Baker S. The impact of albendazole treatment on the incidence of viral- and bacterial-induced diarrhea in school children in southern Vietnam: study protocol for a randomized controlled trial. Trials. 2016 Jun 6;17(1):279. doi: 10.1186/s13063-016-1406-1.
Results Reference
derived
Links:
URL
http://www.oucru.org
Description
Oxford University Clinical research Unit
Learn more about this trial
The Impact of Anthelmintic Treatment on the Incidence of Diarrheal Disease in Vietnamese School Children
We'll reach out to this number within 24 hrs